EMA Moves To Boost Use Of Alternatives To Animal Testing

Alternative approaches to animal models, such as improved tests based on human and animal cells, provide opportunities to develop better and more predictive scientific tools, the European Medicines Agency says.

Organ-on-a-chip (OOC) - microfluidic device chip that simulates biological organs that is type of artificial organ. Prototype of design lab-on-a-chip
Organ-on-chips technology can provide an alternative to animal models • Source: Alamy

The European Medicines Agency has implemented a new measure to minimize animal testing by making its free-of-charge Innovation Task Force (ITF) available to companies for discussions on how to replace, reduce and refine animal use during the development, manufacturing and testing of human and veterinary medicines.

Alternative approaches to animal models include improved tests based on human and animal cells, organoids, organ-on-chips and in silico modeling. They “provide opportunities to develop better and more predictive scientific...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

EU Pharma Reform Package Clears Big Political Hurdle After Council Adopts Position

 

The Council of the EU has made several key amendments to the legislative reform package, which it will now negotiate with the European Parliament.

MHRA Backs Bacteriophage Innovation To Fight Antimicrobial Resistance

 

The UK regulator wants to help companies to develop bacteriophages for the treatment of infections. Its first guidance on this topic offers advice to researchers and sets out the regulatory requirements they will need to meet.

Scientists Work With AI To Uncover ‘Unexpected’ Drug Combos For Breast Cancer

 

A UK research team has used artificial intelligence to find new treatments for cancer using existing US Food and Drug Administration-approved medicines that are not normally not used for the disease.

EMA Official Clarifies Benefits And Limitations Of Innovation Pathways

 

A European Medicines Agency official provided an overview and update of the support the EMA offers developers of innovative products and discussed, among other things, its Innovation Task Force, Quality Innovation Group and a scientific advice pilot for clinical trials.

More from Geography

Scientists Work With AI To Uncover ‘Unexpected’ Drug Combos For Breast Cancer

 

A UK research team has used artificial intelligence to find new treatments for cancer using existing US Food and Drug Administration-approved medicines that are not normally not used for the disease.

Saving Part D: US Medicare Advisors Sound The Alarm

 

The US Medicare Payment Advisory Commission worries that Medicare prescription drug market trends may cause the stand-alone plan portion of the program to “wither away,” which could take the traditional fee-for-service side of Medicare with it.

Clinical Trials Nonprofit Fights for Access Despite DEI Crack-Down

 
• By 

The Clinical Trials Access Collaborative (CTAC) will build on a pilot program's work to bolster community-based clinical research infrastructure so "anyone who wants to participate in clinical trials can and do it closer to home,” CEO Tesheia Harris said in an interview.